Personalis (NASDAQ:PSNL) Trading Down 6.2% – Time to Sell?

Personalis, Inc. (NASDAQ:PSNL)’s share price dropped 6.2% during trading on Monday . The stock traded as low as $6.29 and last traded at $6.31. Approximately 352,259 shares changed hands during trading, a decline of 75% from the average daily volume of 1,422,806 shares. The stock had previously closed at $6.73.

Analyst Ratings Changes

Several analysts recently commented on the company. BTIG Research boosted their price target on Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Morgan Stanley cut their price objective on Personalis from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Thursday, March 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Thursday, January 22nd. Guggenheim upped their target price on shares of Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Wall Street Zen upgraded shares of Personalis from a “sell” rating to a “hold” rating in a research report on Sunday, March 8th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $11.50.

Personalis Trading Down 5.1%

The stock has a fifty day moving average of $7.55 and a two-hundred day moving average of $8.43. The stock has a market capitalization of $668.68 million, a price-to-earnings ratio of -7.02 and a beta of 2.20.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The company had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 39.13% and a negative net margin of 116.69%. Equities analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Hedge funds have recently added to or reduced their stakes in the stock. Royal Bank of Canada increased its position in Personalis by 3.2% in the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after acquiring an additional 2,395 shares in the last quarter. Dynamic Technology Lab Private Ltd lifted its position in shares of Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock worth $269,000 after purchasing an additional 33,044 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Personalis by 55.7% during the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock valued at $998,000 after purchasing an additional 101,706 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Personalis in the first quarter valued at approximately $47,000. Finally, JPMorgan Chase & Co. increased its holdings in shares of Personalis by 505.6% in the second quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock valued at $193,000 after purchasing an additional 24,621 shares in the last quarter. Institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.